New cancer drug enters early human testing
NCT ID NCT06187402
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial is testing an experimental drug called LM-24C5 in about 49 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of shrinking tumors. Participants receive the drug intravenously, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LM-24C5 (an experimental drug given intravenously)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, small trial (49 people) focused on safety and dosing. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvan and Bren Simon Cancer Center
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
-
Mary Crowley Cancer Research Center
NOT_YET_RECRUITINGDallas, Texas, 75230, United States
Contact
-
Ocala Oncology
RECRUITINGOcala, Florida, 34474, United States
Contact
-
The Christ Hospital
NOT_YET_RECRUITINGCincinnati, Ohio, 45219, United States
Contact
-
University of Southern California (USC) - Norris Comprehensive Cancer Center
NOT_YET_RECRUITINGLos Angeles, California, 90089, United States
Contact
-
Virginia Cancer Specialists, P.C.
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
Contact